



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref No:Corp.Sec/BSE/2023-24/88

Dated:30/09/2023

To,
Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Dear Sir,

Sub: Summary of Outcome/Proceeding of the AGM /Disclosure of events or information under Regulation 30 of SEBI (LODR) Regulation -38th Annual General Meeting held on Saturday, 30th September 2023 with Scrip Code 524703.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we enclose Summary of proceedings of the 38th Annual General Meeting held on Saturday, 30th September 2023.

Kindly take above intimation in your record

Thanking You

Yours Faithfully,

For Sandu Pharmaceuticals Limited

PRATIKA MHAMBRAY
Company Secretary



AN ISO 9001:2015 CERTIFIED ORGANISATION
Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in



Summary of Proceeding of the 38th Annual General Meeting of Sandu Pharmaceuticals Limited.

A. Date, time and venue of the Annual General Meeting

The 38th Annual General Meeting of the Company was held on Saturday, 30th September 2023 through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM). The Meeting commenced at 4.30 p.m. (IST) and concluded at 5.42 PM (IST).

B. Proceedings in Brief

- Shri K Vinay Kumar Non Executive Independent Director and Chairman of the Company Chaired the Meeting.
- The requisite Quorum being present, the Chairman called the Meeting to order
- The Chairman informed that the Meeting was held through VC/OAVM in compliance with the circulars issued by the Ministry of Corporate Affairs, Government of India and Securities Exchange Board of India.
- The Company Secretary informed that remote voting commenced on Wednesday, 27th September 2023 at 10.00 am and ended on Friday, 29th September 2023 at 5.00 pm.
- The following items of business as set out in the Notice convening the 38th Annual General Meeting were commended for members consideration and approval

ORDINARY BUSINESS

1. TO ADOPT THE AUDITED STANDALONE FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2023
2. TO ADOPT THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2023
3. TO APPOINT DR MRS SHUBHADA SANDU (DIN: 07148834), WHO RETIRES BY ROTATION AS A DIRECTOR
4. TO DECLARE A DIVIDEND ON EQUITY SHARES FOR THE FINANCIAL YEAR ENDED MARCH 31, 2023

SPECIAL BUSINESS

5. TO APPROVE/PLACE, RELATED PARTY TRANSACTIONS BETWEEN SANDU PHARMACEUTICALS LIMITED AND SANDU BROTHERS PRIVATE LIMITED.
6. RATIFICATION OF COST AUDITOR'S REMUNERATION
7. APPOINTMENT OF ADVOCATE SHRI AJIT RAJARAM KANTAK (DIN:10269866) AS AN NON EXECUTIVE INDEPENDENT DIRECTOR
8. APPOINTMENT OF CA SHRI BALRAMVISHWANATHAN (DIN: 10245195) AS AN NON EXECUTIVE INDEPENDENT DIRECTOR
9. REAPPOINTMENT OF MANAGING DIRECTOR

- The Chairman also informed the members that Shri Swapnil Dixit, Practising Company Secretary was appointed as Scrutinizer to Scrutinize the voting through electronic means (i.e remote e-voting and voting at the meeting by using electronic system).
- The Chairman informed the members that the results of evoting shall be intimated to the stock exchange and also uploaded on the website of the Company and NSDL.

C. Voting by Members:

- The Company had provided remote evoting facility to its members to cast votes electronically on all 9 items of business set out in the Notice.
- Further the facility to vote on resolutions through electronic voting system at the Annual General meeting was made available to the members who participated in the meeting and had not cast their votes through remote e-voting

Annexure A - Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular *CIRICFD/CMD/4/2015* dated September 9, 2015

Name of the Director	Adv. Shri. Ajit Rajaram Kantak	CA Shri Balaram Vishwanathan	Shri Umesh B Sandu
Date of Birth	29/08/1957	12/04/1968	17/02/1967
Nationality	Indian	Indian	Indian
Date of appointment/ Reappointment on the Board	14/08/2023	14/08/2023	29/08/2020
Qualifications	BSC, LLB,LLM	B.Com. FCA, CPA(USA)	B.com, LLB, CS
Expertise in specific functional area	Shri Ajit Kantak is a Practising Advocate having completed LLB degree from the University of Bombay in the year 1981 and LLM from University of Pune in the year 1986.	Audit, Tax, M&A Advisory, Due Diligence, Compliance and Valuation services along with financial control, planning & analysis, regulatory reporting, business strategy, treasury and risk management experience gained in large International Banks.	Shri Umesh B Sandu (01132141) is a Commerce and Law Graduate from Mumbai University and also qualified Company Secretary from ICSI.
Number of shares held in the company	NIL	NIL	1388693
List of the directorship held in other Companies.	NIL	NIL	NIL
Chairman/Member in the Committee of the Boards of Companies in which he is Director (including Pvt Company)	NIL	NIL	Member of Audit Committee and Stakeholder Relationship Committee.
Relationship between directors in terse and relationships with other Key Managerial Personnel of the Company	Adv. Shri. Ajit Rajaram Kantak is not related to any other Director and/or Key Managerial Personnel of the Company	CA Shri. Balram Vishwanathan is not related to any other Director and/or Key Managerial Personnel of the Company	Shri Umesh B Sandu is not related to any other Director and/or Key Managerial Personnel of the Company other than Shri Shashank Sandu and Dr Shubhada Sandu
Terms & conditions of appointment/ reappointments	Shri Ajit Rajaram Kantak is a Non-Executive Independent Director. he is not liable to retire by rotation	CA Shri. Balram Vishwanathan is a Non-Executive Independent Director. He is not liable to retire by rotation.	Shri Umesh B Sandu is a Executive Director. he is not liable to retire by rotation.

For Sandu Pharmaceuticals Limited

Pratika Mhambray
Company Secretary